Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The “underappreciated” partnership opportunity with Roche ...

Detailed price information for Zealand Pharma A/S (ZLDPF) from The Globe and Mail including charting and trades.

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Hold rating on Vicarious Surgical. The company’s shares closed last Monday at $9.63. According to TipRanks.com, Zimmerman is ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a global Phase 2b trial in people with obesity or ...

Wall Street's major averages closed in the green on Friday, but the benchmark S&P 500 (SP500) posted a four-week losing streak for the first time since early August last year as President Donald ...

Check Out Our Latest Analysis on ZLDPF Zealand Pharma A/S Stock Performance Zealand Pharma A/S stock opened at $84.50 on Friday. The stock’s 50-day moving average is $97.35 and its 200-day ...

Overview: Zealand Pharma A/S is a biotechnology company focused on discovering, developing, and commercializing peptide-based medicines in Denmark and the United States, with a market ...